Lameness Repair Company

PetVivo Enhances Its Proprietary Position with Key US Patent Grant

News Release



PetVivo Enhances Its Proprietary Position with Key US Patent Grant


MINNEAPOLIS, MN May 20th, 2015 PetVivo Holdings, Inc. (OTCPINK:PETV) an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and therapeutics for pets is pleased to announce that the United States Patent and Trademark Office (USPTO) has allowed an important patent related to wound healing treatments. The open-ended nature of the issued claims in this patent, entitled “Protein Biomaterials and Biocoacervates and Methods of Making and Using Thereof,” provides tremendous proprietary protection for a broad range of wound healing treatments, including the treatment of osteoarthritis.


“Our biomaterial technology and the claims issued in our patents provide us extremely comprehensive coverage. This divisional patent extends our patent claims to include the use of our particles for wound healing applications, as well as the use of this proprietary material in any shape or coating to greatly extend the scope of our device and drug delivery applications,” noted PetVivo Chief Technology Officer, Dr. David Masters. “In addition, the claims covering wound healing devices disclosed in this newly allowed patent application provides proprietary protection for our Kush™ Canine particles.”


With this recent wound healing patent allowance by the USPTO, PetVivo’s intellectual property portfolio has grown to twenty allowed patents, eight of which are United States patents. PetVivo has an additional sixteen patent applications pending in the US and in strategic foreign countries.


“It is exciting to see the ongoing expansion of our intellectual property. This expansion highlights the novelty of our biomaterials, devices and treatments including our lead product Kush Canine,” commented PetVivo CEO John Lai. “We look forward to improving the quality of life for osteoarthritic dogs and their owners with the launch of Kush Canine slated for later this year.”


PetVivo diligently protects its proprietary technologies, including the composition of raw elements used to produce its formulations, the fabricated biomaterials and their application in end products and devices. To maximize the strength and value of its intellectual property the claims generally cover the commercial devices/therapeutics, the manufacturing methods and the methods of use of PetVivo’s proprietary technology.


PetVivo recently completed a merger with Gel-Del Technologies. As a wholly-owned subsidiary of PetVivo Holdings, Gel-Del Technologies will continue its operations as the manufacturing and product development division of PetVivo Holdings.


About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.


PetVivo’s strategy is to acquire or in-license proprietary products from human medical device companies specifically for the companion animal market. The company’s pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.


For more information, visit:


Forward-Looking Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

Real Time Web Analytics